Calluna Pharma successfully completes Phase 1 clinical study of CAL101, a first-in-class therapeutic for fibrotic and fibro-inflammatory indications

Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced the completion of Phase 1 clinical study for CAL101, Calluna’s lead product candidate.

FDA issues guidance on using real-world data for drug development – Pharmaceutical Technology

Under Section 505 of the Cures Act, the FDA was mandated to create a framework on how real-world evidence and data could be used in

August 31, 2023

ONC Launches Platform for Organizing and Building USCDI+ Datasets

What You Should Know: – Today, the Office of the National Coordinator for Health Information Technology (ONC) has officially launched a new platform dedicated to

December 7, 2023

Heat waves associated with increased risk of preterm birth in the U.S.

Heat waves are becoming more frequent and more intense, posing more of a health risk around the world. High temperatures can be deadly, and are

May 28, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.